Trending NewsTrending NewsNASDAQ:VKTX Viking Therapeutics (VKTX) Stock Price, News & Analysis $27.28 +0.42 (+1.56%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$26.88 -0.40 (-1.45%) As of 10/30/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Viking Therapeutics Stock (NASDAQ:VKTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Viking Therapeutics alerts:Sign Up Key Stats Today's Range$26.31▼$27.8350-Day Range$24.21▼$41.6552-Week Range$23.82▼$43.15Volume5.13 million shsAverage Volume5.18 million shsMarket Capitalization$3.44 billionP/E RatioN/ADividend YieldN/APrice Target$92.27Consensus RatingModerate Buy Company Overview Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company develops therapies for metabolic and endocrine disorders, with a focus on conditions involving obesity, nonalcoholic steatohepatitis (NASH), and other liver and lipid disorders. Viking’s lead program is VK2735, an investigational dual GLP-1/GIP receptor agonist being developed in injectable and oral formulations for obesity and related metabolic conditions. The company is also developing VK2809, an oral, liver-selective thyroid hormone receptor beta agonist intended for the treatment of NASH and associated lipid disorders. Its pipeline has included additional therapies for rare metabolic diseases. Viking conducts research and clinical development primarily in the United States, with its therapies still in development and not broadly marketed as approved commercial products. The company is led by Brian Lian, Ph.D., who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Viking Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreVKTX MarketRank™: 3.140172278775 of 5 starsViking Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 410th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingViking Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.79, and is based on 2 strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialViking Therapeutics has a consensus price target of $92.27, representing about 238.2% upside from its current price of $27.28.Amount of Analyst CoverageViking Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Viking Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Viking Therapeutics are expected to grow in the coming year, from ($5.26) to ($5.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Viking Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Viking Therapeutics is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioViking Therapeutics has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.41% of the float of Viking Therapeutics has been sold short.Short Interest Ratio / Days to CoverViking Therapeutics has a short interest ratio ("days to cover") of 4.38.Change versus previous monthShort interest in Viking Therapeutics has recently decreased by 1.48%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldViking Therapeutics does not currently pay a dividend.Dividend GrowthViking Therapeutics does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.03 News SentimentViking Therapeutics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Viking Therapeutics this week, compared to 8 articles on an average week.Search InterestOnly 31 people have searched for VKTX on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.MarketBeat Follows24 people have added Viking Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 140% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Viking Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders5.30% of the stock of Viking Therapeutics is held by insiders.Percentage Held by Institutions76.03% of the stock of Viking Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Viking Therapeutics' insider trading history. Receive VKTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VKTX Stock News HeadlinesViking Therapeutics Bets Big on VK2735 in Earnings CallOctober 31 at 4:14 PM | theglobeandmail.comViking Therapeutics: A Strong Injection, A Scaled-Back PillOctober 31 at 4:39 AM | seekingalpha.comWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal. Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30.October 31 at 1:00 AM | Brownstone Research (Ad)Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Genmab (GMAB)October 30 at 3:11 PM | theglobeandmail.comBrokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a BetOctober 30 at 10:10 AM | finance.yahoo.comViking Therapeutics: Q3 Update - Why You Can't Discount This GLP-1 Player (Yet)October 29 at 7:08 PM | seekingalpha.comEli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics EasesOctober 29 at 10:03 AM | 247wallst.com3 Emerging Biotech Stocks With Significant Upside Potential (VKTX)Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.October 1, 2026 | marketbeat.comSee More Headlines VKTX Stock Analysis - Frequently Asked Questions How have VKTX shares performed this year? Viking Therapeutics' stock was trading at $35.18 at the beginning of the year. Since then, VKTX shares have decreased by 22.5% and is now trading at $27.28. How were Viking Therapeutics' earnings last quarter? Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its quarterly earnings results on Wednesday, October, 28th. The biotechnology company reported ($1.55) earnings per share for the quarter, missing analysts' consensus estimates of ($1.06) by $0.49. Read the conference call transcript. When did Viking Therapeutics IPO? Viking Therapeutics (VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at a price of $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager. Who are Viking Therapeutics' major shareholders? Top institutional investors of Viking Therapeutics include Oppenheimer & Co. Inc. (0.15%), IFP Advisors Inc (0.05%), Profund Advisors LLC (0.04%) and MN Wealth Advisors LLC (0.02%). Insiders that own company stock include Brian Lian, Marianna Mancini, Greg Zante, Matthew W Foehr, Lawson Macartney, Charles A Rowland Jr, J Matthew Singleton, Neil William Aubuchon and Sarah Kathryn Rouan. View institutional ownership trends. How do I buy shares of Viking Therapeutics? Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Viking Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Viking Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Palantir Technologies (PLTR), Broadcom (AVGO) and NIO (NIO). Company Calendar Last Earnings10/28/2026Today10/31/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, VKTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:VKTX CIK1607678 Webwww.vikingtherapeutics.com Phone(858) 704-4660FaxN/AEmployees65Year Founded2012Price Target and Rating Average Price Target for Viking Therapeutics$92.27 High Price Target$125.00 Low Price Target$34.00 Potential Upside/Downside+238.2%Consensus RatingModerate Buy Rating Score (0-4)2.79 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($5.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$359.64 million Net MarginsN/A Pretax MarginN/A Return on Equity-121.45% Return on Assets-101.93% Debt Debt-to-Equity RatioN/A Current Ratio4.72 Quick Ratio4.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.65 per share Price / Book4.83Miscellaneous Outstanding Shares125,990,000Free Float119,310,000Market Cap$3.44 billion OptionableOptionable Beta0.66 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:VKTX) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersYour free stock pick for todayElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredCigar Lake Flooded Again Uranium Supply Shock RepeatsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
